DE69926630T2 - Antikörper gegen die ed-b domäne von fibronektin, solche antikörper enthaltende konjugate, und deren verwendung zur diagnose und therapie von angiogenese-assoziierten tumoren und krankheiten - Google Patents
Antikörper gegen die ed-b domäne von fibronektin, solche antikörper enthaltende konjugate, und deren verwendung zur diagnose und therapie von angiogenese-assoziierten tumoren und krankheiten Download PDFInfo
- Publication number
- DE69926630T2 DE69926630T2 DE69926630T DE69926630T DE69926630T2 DE 69926630 T2 DE69926630 T2 DE 69926630T2 DE 69926630 T DE69926630 T DE 69926630T DE 69926630 T DE69926630 T DE 69926630T DE 69926630 T2 DE69926630 T2 DE 69926630T2
- Authority
- DE
- Germany
- Prior art keywords
- antibody
- antibodies
- domain
- angiogenesis
- fibronectin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7533898A | 1998-05-11 | 1998-05-11 | |
| US75338 | 1998-05-11 | ||
| US300425 | 1999-04-28 | ||
| US09/300,425 US20030045681A1 (en) | 1998-05-11 | 1999-04-28 | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
| PCT/EP1999/003210 WO1999058570A2 (en) | 1998-05-11 | 1999-05-11 | Antibodies to the ed-b domain of fibronectin, conjugates containing them and use therefor for diagnosis and therapy of tumors and diseases associated with angiogenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69926630D1 DE69926630D1 (de) | 2005-09-15 |
| DE69926630T2 true DE69926630T2 (de) | 2006-05-24 |
Family
ID=26756726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69926630T Expired - Lifetime DE69926630T2 (de) | 1998-05-11 | 1999-05-11 | Antikörper gegen die ed-b domäne von fibronektin, solche antikörper enthaltende konjugate, und deren verwendung zur diagnose und therapie von angiogenese-assoziierten tumoren und krankheiten |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20070189963A1 (et) |
| EP (1) | EP1084145B1 (et) |
| JP (1) | JP2002514405A (et) |
| CN (1) | CN1250571C (et) |
| AT (1) | ATE301676T1 (et) |
| AU (1) | AU759207B2 (et) |
| BR (1) | BRPI9910394B8 (et) |
| CA (1) | CA2333833C (et) |
| CZ (1) | CZ300495B6 (et) |
| DE (1) | DE69926630T2 (et) |
| DK (1) | DK1084145T3 (et) |
| EA (1) | EA005685B1 (et) |
| EE (1) | EE05435B1 (et) |
| ES (1) | ES2247802T3 (et) |
| HU (1) | HU225675B1 (et) |
| IL (1) | IL139452A0 (et) |
| IS (1) | IS2522B (et) |
| NO (1) | NO327732B1 (et) |
| NZ (1) | NZ508600A (et) |
| PL (1) | PL199353B1 (et) |
| SK (1) | SK286822B6 (et) |
| TR (1) | TR200003317T2 (et) |
| TW (1) | TWI259837B (et) |
| WO (1) | WO1999058570A2 (et) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| JP5483789B2 (ja) * | 1999-01-05 | 2014-05-07 | ザ フリンダーズ ユニバーシティ オブ サウス オーストラリア | 眼障害を治療及び診断するための新規な薬物及び方法 |
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| DE19947559A1 (de) * | 1999-09-24 | 2001-04-19 | Schering Ag | Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung |
| US6319273B1 (en) * | 1999-12-16 | 2001-11-20 | Light Sciences Corporation | Illuminating device for treating eye disease |
| AU2001242432B2 (en) * | 2000-02-24 | 2007-11-08 | Eidgenossische Technische Hochschule Zurich | Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis |
| PT1719528E (pt) * | 2000-02-24 | 2012-01-06 | Philogen Spa | Composições e métodos para tratamento de angiogénese em lesões patológicas |
| DE10045803A1 (de) * | 2000-09-07 | 2002-04-11 | Schering Ag | Rezeptor der EDb Fibronektin-Domäne |
| US20020197700A1 (en) * | 2000-09-07 | 2002-12-26 | Schering Ag | Receptor of the EDb-fibronectin domains |
| US20030100010A1 (en) * | 2001-11-23 | 2003-05-29 | George Jackowski | Fibrinogen biopolymer Marker predictive of type II diabetes |
| US20030118657A1 (en) * | 2001-12-04 | 2003-06-26 | West Jennifer L. | Treatment of disease states characterized by excessive or inappropriate angiogenesis |
| ES2346750T3 (es) * | 2002-01-03 | 2010-10-20 | Bayer Schering Pharma Aktiengesellschaft | Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y su uso para la deteccion y tratamiento de tumores. |
| BR0306715A (pt) * | 2002-01-03 | 2004-12-28 | Schering Ag | Métodos para diagnóstico e tratamento de tumores |
| CN100535013C (zh) | 2002-03-11 | 2009-09-02 | 菲洛根股份公司 | 应用抗体分子对肿瘤血管进行选择性定向 |
| DK1537146T3 (da) | 2002-07-15 | 2011-04-04 | Univ Texas | Antistoffer, der binder til anioniske phospholipider og aminophospholipider, og deres anvendelse til behandling af virusinfektioner |
| DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
| DE10348319A1 (de) * | 2003-10-17 | 2005-05-19 | Schering Ag | Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques |
| US7785591B2 (en) | 2004-10-14 | 2010-08-31 | Morphosys Ag | Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
| US8679490B2 (en) * | 2005-11-07 | 2014-03-25 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
| WO2007054120A1 (de) * | 2005-11-09 | 2007-05-18 | Bayer Schering Pharma Aktiengesellschaft | Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern |
| EP1842553A1 (en) * | 2006-04-07 | 2007-10-10 | Bayer Schering Pharma Aktiengesellschaft | Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule |
| EP1925664A1 (en) | 2006-11-15 | 2008-05-28 | Scil proteins GmbH | Artificial binding proteins based on a modified alpha helical region of ubiquitin |
| EP2085095B1 (en) | 2008-01-17 | 2012-03-07 | Philogen S.p.A. | Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart |
| EP2100621A1 (en) | 2008-03-10 | 2009-09-16 | mivenion GmbH | Polyether polyol dendron conjugates with effector molecules for biological targeting |
| JP2009244154A (ja) | 2008-03-31 | 2009-10-22 | Nationa Hospital Organization | 老化、および血管障害を伴う疾患の検定のための組成物、キットおよび方法 |
| EP2116555A1 (en) | 2008-05-08 | 2009-11-11 | Bayer Schering Pharma Aktiengesellschaft | Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma |
| US20110306065A1 (en) * | 2008-11-12 | 2011-12-15 | The Trustees Of The University Of Pennsylvania | Use of an antibody and a rare-earth based crystal |
| DK2379581T3 (da) | 2009-12-14 | 2014-01-06 | Scil Proteins Gmbh | Fremgangsmåde til identifikation af hetero-multimerisk modificerede ubiquitinproteiner med evne til binding til ligander |
| WO2011110490A1 (en) | 2010-03-09 | 2011-09-15 | Bayer Pharma Aktiengesellschaft | Process for the production of radioactively labelled scfv antibody fragments, kits and compositions |
| AU2012268970B2 (en) | 2011-06-15 | 2016-01-28 | Navigo Proteins Gmbh | Dimeric binding proteins based on modified ubiquitins |
| WO2012171541A1 (en) | 2011-06-15 | 2012-12-20 | Scil Proteins Gmbh | Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins |
| EP2734232B1 (en) | 2011-07-19 | 2017-11-01 | Philogen S.p.A. | Sequential anti-ctla4 and targeted il-2 therapy |
| RU2481839C2 (ru) * | 2011-08-16 | 2013-05-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный медицинский университет Министерства здравоохранения и социального развития" | Способ лечения ишемической болезни сердца с дистальным или диффузным поражением коронарных артерий |
| US20150183846A1 (en) | 2012-06-13 | 2015-07-02 | Scil Proteins Gmbh | Human fusion proteins comprising single chain tnfalpha and targeting domains |
| WO2014094799A1 (en) | 2012-12-19 | 2014-06-26 | Scil-Proteins-Gmbh | Ubiquitin moieties as a means for prolonging serum half-life |
| EP3029065B1 (en) * | 2013-06-06 | 2020-05-27 | Hefei Lifeon Pharmaceutical Co. Ltd. | Human antibody against ed-b domain of fibronectin and uses thereof |
| EP3253785B1 (en) | 2015-02-06 | 2019-04-10 | Navigo Proteins Gmbh | Novel egfr binding proteins |
| DK3322721T3 (da) | 2015-07-16 | 2022-03-14 | Navigo Proteins Gmbh | Nye immunglobulin-bindende proteiner og deres anvendelse i affinitetsoprensning |
| CA2991815A1 (en) | 2015-07-20 | 2017-01-26 | Navigo Proteins Gmbh | Novel binding proteins based on di-ubiquitin muteins and methods for generation |
| US20180340936A1 (en) * | 2015-11-16 | 2018-11-29 | Hefei Lifeon Pharmaceutical Co. Ltd. | Use of ed-b protein in diagnosis of tissue hyperplasia |
| CA3022751A1 (en) | 2016-05-04 | 2017-11-09 | Navigo Proteins Gmbh | Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker |
| GB201612317D0 (en) | 2016-07-15 | 2016-08-31 | Philogen Spa | Antibody compositions |
| US11230576B2 (en) | 2016-08-11 | 2022-01-25 | Navigo Proteins Gmbh | Alkaline stable immunoglobulin-binding proteins |
| US20190269791A1 (en) | 2016-10-17 | 2019-09-05 | Pfizer Inc. | Anti-edb antibodies and antibody-drug conjugates |
| GB201621806D0 (en) | 2016-12-21 | 2017-02-01 | Philogen Spa | Immunocytokines with progressive activation mechanism |
| CN111148759B (zh) * | 2017-09-30 | 2023-09-19 | 合肥立方制药股份有限公司 | 结合至纤维连接蛋白b结构域的蛋白 |
| EP3706804B1 (en) | 2017-11-07 | 2022-02-23 | Navigo Proteins GmbH | Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer |
| WO2019185792A1 (en) | 2018-03-29 | 2019-10-03 | Philogen S.P.A | Cancer treatment using immunoconjugates and immune check-point inhibitors |
| WO2020070150A1 (en) | 2018-10-02 | 2020-04-09 | Philogen S.P.A | Il2 immunoconjugates |
| EP3660039A1 (en) | 2018-11-30 | 2020-06-03 | Philogen S.p.A. | Il2 immunoconjugates |
| KR20240024242A (ko) | 2021-06-23 | 2024-02-23 | 싸이튠 파마 | 인터루킨-15 기반 면역 사이토카인 |
| MX2023015400A (es) | 2021-06-23 | 2024-03-07 | Cytune Pharma | Variantes de interleucina 15. |
| EP4440599A1 (en) | 2022-01-04 | 2024-10-09 | Philogen S.p.A. | Combination of an immunocytokine comprising il-12 and a kinase inhibitor |
| WO2024028258A1 (en) | 2022-08-01 | 2024-02-08 | Philochem Ag | Conjugates of psma-binding moieties with cytotoxic agents |
| WO2024047237A1 (en) | 2022-09-01 | 2024-03-07 | Philogen S.P.A. | Tnf alpha and interleukin-2 combination therapy for non-melanoma skin cancer |
| WO2024052333A1 (en) | 2022-09-06 | 2024-03-14 | Philochem Ag | Multivalent fibroblast activation protein ligands for targeted delivery applications |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9610967D0 (en) * | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
-
1999
- 1999-05-10 TW TW088107648A patent/TWI259837B/zh active
- 1999-05-11 WO PCT/EP1999/003210 patent/WO1999058570A2/en active IP Right Grant
- 1999-05-11 CA CA2333833A patent/CA2333833C/en not_active Expired - Lifetime
- 1999-05-11 BR BRPI9910394 patent/BRPI9910394B8/pt not_active IP Right Cessation
- 1999-05-11 SK SK1679-2000A patent/SK286822B6/sk not_active IP Right Cessation
- 1999-05-11 EP EP99923571A patent/EP1084145B1/en not_active Expired - Lifetime
- 1999-05-11 AT AT99923571T patent/ATE301676T1/de active
- 1999-05-11 HU HU0102992A patent/HU225675B1/hu not_active IP Right Cessation
- 1999-05-11 CZ CZ20004216A patent/CZ300495B6/cs not_active IP Right Cessation
- 1999-05-11 DK DK99923571T patent/DK1084145T3/da active
- 1999-05-11 IL IL13945299A patent/IL139452A0/xx unknown
- 1999-05-11 EE EEP200000802A patent/EE05435B1/et not_active IP Right Cessation
- 1999-05-11 NZ NZ508600A patent/NZ508600A/xx unknown
- 1999-05-11 ES ES99923571T patent/ES2247802T3/es not_active Expired - Lifetime
- 1999-05-11 CN CNB998060526A patent/CN1250571C/zh not_active Expired - Lifetime
- 1999-05-11 PL PL345845A patent/PL199353B1/pl not_active IP Right Cessation
- 1999-05-11 DE DE69926630T patent/DE69926630T2/de not_active Expired - Lifetime
- 1999-05-11 AU AU40398/99A patent/AU759207B2/en not_active Expired
- 1999-05-11 JP JP2000548372A patent/JP2002514405A/ja active Pending
- 1999-05-11 EA EA200001169A patent/EA005685B1/ru not_active IP Right Cessation
- 1999-05-11 TR TR2000/03317T patent/TR200003317T2/xx unknown
-
2000
- 2000-11-10 IS IS5708A patent/IS2522B/is unknown
- 2000-11-10 NO NO20005694A patent/NO327732B1/no not_active IP Right Cessation
-
2006
- 2006-12-13 US US11/637,810 patent/US20070189963A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69926630T2 (de) | Antikörper gegen die ed-b domäne von fibronektin, solche antikörper enthaltende konjugate, und deren verwendung zur diagnose und therapie von angiogenese-assoziierten tumoren und krankheiten | |
| US8097254B2 (en) | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis | |
| DE69737683T2 (de) | Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen | |
| JP2009280607A (ja) | フィブロネクチンのｅｄ−ｂドメインに対する抗体、それを含有する抱合体、および、腫瘍および血管新生関連の疾病の診断および治療をするためのそれの用途 | |
| Birchler et al. | Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment | |
| DE60317677T2 (de) | Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung | |
| AU2001242432A1 (en) | Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis | |
| CN107709361A (zh) | 用于治疗突触核蛋白病的药剂、用途和方法 | |
| DE69927268T2 (de) | Spezifische antikörper enthaltende bindungsproteine die das nekrotische tumorzentrum binden und deren verwendung | |
| BR112016017649B1 (pt) | Polipeptídeo isolado compreendendo substratos de matriptase e de ativador do plasminogênio u e outras porções cliváveis, composição farmacêutica compreendendo o dito polipeptídeo, bem como métodos para produzir e fabricar um polipeptídeo isolado compreendendo uma porção clivável e uso da composição farmacêutica e quantidade terapeuticamente eficaz da dita composição no tratamento de um distúrbio ou doença | |
| DE69612509T2 (de) | Spezifische bindungspartner fuer menschliches karzinoembryonisches antigen, substanzen und methoden | |
| EA010653B1 (ru) | Нацеливание на опухолевую сосудистую сеть при использовании меченного радиоактивным изотопом антитела l19 к ed-b фибронектину | |
| US20030176663A1 (en) | Specific binding molecules for scintigraphy | |
| BG65163B1 (bg) | Антитела за ed-b домен на фибронектин, съдържащи ги конюгации и използването им за диагноза и лечение на тумори и болестни състояния, свързани с ангиогенезата | |
| MXPA00011017A (en) | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis | |
| KR100494530B1 (ko) | 피브로넥틴ed-b도메인에대한항체,그제조방법및용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |